Respiratorius AB Company Description

Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma.

The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma.

Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.

Respiratorius AB (publ)

Country	Sweden
Founded	1998
Industry	Biological Products, Except Diagnostic Substances
Employees	1
CEO	Johan Drott

Contact Details

Address: Medicon Village Lund, 223 81 Sweden
Phone	46 7 09 22 41 40
Website	respiratorius.com

Stock Details

Ticker Symbol	RESP
Exchange	Spotlight Stock Market
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2836

Key Executives

Name	Position
Johan Drott	Chief Executive Officer